Clinical trials: Nab-paclitaxel
Relapsed Breast Cancer, Neoplasms, Breast
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or…
- Trial name
- NCT00479856
- Testing
- Lapatinib, Capecitabine, Docetaxel
- Where
- 28 sites in United States
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03776812
- Testing
- Relacorilant, Nab-paclitaxel
- Where
- 24 sites in United States, Belgium and 3 more
- Volunteers
- 178 people
- Sponsor
- Corcept Therapeutics
Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated.
- Conditions
- Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas
- Trial name
- VIRAGE2 (NCT07701486)
- Testing
- VCN-01 oncolytic adenovirus (zabilugene almadenorepvec), Nab-paclitaxel + Gemcitabine
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Theriva Biologics SL
Advanced or Metastatic Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors.
- Trial name
- NCT05017012
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab, Pemetrexed
- Where
- 22 sites in Chile, Hungary and 4 more
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Advanced Pancreatic Carcinoma
HCW9218 for Advanced Pancreatic Cancer
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.
- Trial name
- NCT05304936
- Testing
- HCW9218, Gemcitabine (GEM), Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- ImmunityBio, Inc.
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Solid Tumors, Advanced Malignancies
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with…
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02265510
- Testing
- INCB052793, gemcitabine, nab-paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Triple Negative Breast Cancer
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with pembrolizumab therapy.
- Trial name
- NCT03567720
- Testing
- tavokinogene telseplasmid, Pembrolizumab, Immunopulse
- Where
- 14 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- OncoSec Medical Incorporated
Cancer
GSK1120212 Rollover Study
This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.
- Trial name
- NCT01376310
- Testing
- GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212
- Where
- 19 sites in United States, Canada and 4 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Cancer
Treatment of Pancreatic Cancer With Abraxane
This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine.
- Trial name
- NCT02555813
- Testing
- Abraxane, Gemcitabine
- Where
- 19 sites in Austria
- Volunteers
- 317 people
- Sponsor
- Celgene
Pancreatic Cancer
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in…
- Trial name
- NCT06119217
- Testing
- TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 194 people
- Sponsor
- Trishula Therapeutics, Inc.
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative…
- Trial name
- NCT05227664
- Testing
- AK117, AK112, Nab paclitaxel
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
- Trial name
- CANOPY-1 (NCT03631199)
- Testing
- canakinumab, pembrolizumab, carboplatin
- Where
- 152 sites in United States, Argentina and 39 more
- Volunteers
- 673 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with…
- Trial name
- NUMANTIA (NCT04827953)
- Testing
- Gemcitabine, Nab paclitaxel, NLM-001
- Where
- 6 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Nelum Corp
Neoplasms, Breast
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709761
- Testing
- Lapatinib/nab-Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.
Non-small Cell Lung Cancer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.
- Trial name
- NCT03169738
- Testing
- avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.